Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-15
2008-01-15
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S277000, C546S282400, C549S447000
Reexamination Certificate
active
11011887
ABSTRACT:
The present invention relates to compounds of formula Iwherein R1is as defined in the specificationand to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or prevention of diseases such as depression, schizophrenia, Parkinson's disease, and to improve cognition.
REFERENCES:
patent: 5389653 (1995-02-01), Bernauer et al.
patent: 0 426 468 (1991-05-01), None
“Understanding Parkinson's Disease” http://www.stalevo.com/info/simplystated/parkinsons—disease—treatment.jsp?checked=y downloaded from the Internet Jul. 15, 2004.
“Parkinson's Treatments: L-dopa” <http://www.macalester.edu/˜psych/whathap/UBNRP/parkinsons/ldopa.html> downloaded from the Internet Jul. 15, 2004.
Mannisto, P.T., et al, Pharmacological Reviews, Williams and Wilkins Inc., pp. 593-628 (1999), XP001203431.
Eric K. Yau, et al, Journal of Organic Chemistry, vol. 55, No. 10, pp. 3147-3158 (1990), XP002343637.
Christian Lerner, et al., Angewandte Chemie. International Edition, vol. 40, No. 21, pp. 4040-4042 (2001), XP002343638.
Christian Lerner, et al., Helvetica Chimica Acta., vol. 86, No. 4, pp. 1045-1061 (2003), XP002343640.
Nishimura, K et al., Angew. Chem. Int. Ed. 2001, vol. 40, No. 2, pp. 440-442.
Lerner, C. et al., Org. Biomol. Chem., 2003, vol. 1, pp. 42-49.
Masjost, B. et al., Chem. Eur. J., 2000, vol. 6, No. 6, pp. 971-982.
Fava, M. et al., J. Clin. Psychopharmacol. vol. 19(4), 1999, pp. 329-335.
Weickert, C. et al., Schizophr. Bull., 1998, vol. 24, pp. 303-316.
Weinberger, D. et al., Biol. Psychiatry, 2001, vol. 50, pp. 825-844.
Egan, M. et al., Proc. Natl. Acad. Sci. USA, 2001, vol. 98, pp. 6917-6922.
Kurth, M. et al., Neurology, 1997, vol. 48, pp. 81-87.
Myllylä, V. et al., European Journal of Neurology, vol. 4, 1997, pp. 333-341 (Handbook of Parkinson's Disease (3rdEd.)) and Pfeiffer, R., Catechol-O-Methyltransferase in Parkinson's Disease, vol. 20, pp. 437-451.
Gershanik, O. et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, 2003, pp. 963-971.
Lachman, H. et al., Pharmacogenetics, 1996, vol. 6, pp. 243-250.
Malhorta, A. et al., Am. J. Psychiatry, 2002, vol. 159, pp. 652-654.
Smith, K. et al., Chem. Res. Toxicol, 2003, vol. 16, pp. 123-128.
d'Ischia, M. et al., Bioorganic & Medicinal Chemistry, 1995, vol. 3, pp. 923-927.
Diederich François
Jakob-Roetne Roland
Lerner Christian
Paulini Ralph
Berch Mark L.
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
LandOfFree
COMT inhibitors for the treatment of depression and impaired... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with COMT inhibitors for the treatment of depression and impaired..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and COMT inhibitors for the treatment of depression and impaired... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3946814